1.Landheim, A, Bakken, K, Vaglum, P. Gender differences in the prevalence of symptom disorders and personality disorders among poly-substance abusers and pure alcoholics. Substance abusers treated in two counties in Norway. Eur Addict Res. 2003;9:8–17.
2.Devries, K, Child, J, Bacchus, L, et al. Intimate partner violence victimization and alcohol consumption in women: a systematic review and meta-analysis. Addiction. 2014;109:379–91.
3.Gil-Rivas, V, Fiorentine, R, Anglin, M. Sexual abuse, physical abuse, and posttraumatic stress disorder among women participating in outpatient drug abuse treatment. J Psychoactive Drugs. 1996;28:95–102.
4.Latimer, W, Stone, A, Voight, A, Winters, K, August, G. Gender differences in psychiatric comorbidity among adolescents with substance use disorders. Exp Clin Psychopharmacol. 2002;10:310–15.
5.Moyer, V, Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2013 Aug 6;159(3):210–18.
7.Centers for Disease Control and Prevention (CDC).Alcohol use and binge drinking among women of childbearing age–United States, 2006–2010. MMWR Morb Mortal Wkly Rep. 2012;61:534–8.
8.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, DC: American Psychiatric Association; 2013.
10.Ashley, M, Olin, J, le Riche, W, et al. Morbidity in alcoholics: evidence for accelerated development of physical disease in women. Arch Intern Med. 1977;137:883–7.
11.Hommer, D, Momenan, R, Kaiser, E, Rawlings, R. Evidence for a gender-related effect of alcoholism on brain volumes. Am J Psychiatry. 2001;158:198–204.
12.Loft, S, Olesen, K, Døssing, M. Increased susceptibility to liver disease in relation to alcohol consumption in women. Scand J Gastroenterol. 1987;22:1251–6.
13.O’Keefe, J, Bhatti, S, Bajwa, A, et al. Alcohol and cardiovascular health: the dose makes the poison … or the remedy. Mayo Clin Proc. 2014;89:382–93.
14.American College of Obstetricians and Gynecologists.ACOG Committee Opinion No. 422: at-risk drinking and illicit drug use: ethical issues in obstetric and gynecologic practice. Obstet Gynecol. 2008;112:1449–60.
15.Willenbring, M, Massey, S, Gardner, M. Helping patients who drink too much: an evidence-based guide for primary care clinicians. Am Fam Physician. 2009;80:44–50.
16.Anton, R, Myrick, H, Wright, T, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011;168:709–17.
17.Jonas, D, Amick, H, Feltner, C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311:1889–90.
18.Moos, R, Moos, B. Long-term influence of duration and intensity of treatment on previously untreated individuals with alcohol use disorders. Addiction. 2003;98:325–37.
19.Bertholet, N, Daeppen, J, Wietlisbach, V, et al. Reduction of alcohol consumption by brief alcohol intervention in primary care: systematic review and meta-analysis. Arch Intern Med. 2005;165:986–95.
20.Kleber, H. Pharmacologic treatments for heroin and cocaine dependence. Am J Addict. 2003;12(Suppl 2):S5–S18.
21.Patrick, M, Schulenberg, J. Prevalence and predictors of adolescent alcohol use and binge drinking in the United States. Alcohol Res. 2013;35:193–200.
22.Wilson, C, Sherritt, L, Gates, E, Knight, J. Are clinical impressions of adolescent substance use accurate? Pediatrics. 2004;114:e536–40.
23.Knight, J, Sherritt, L, Harris, S, et al. Validity of brief alcohol screening tests among adolescents: a comparison of the AUDIT, POSIT, CAGE, and CRAFFT. Alcohol Clin Exp Res. 2003;27:67–73.
24.Barry, K, Caetano, R, Cheng, G, et al. Reducing Alcohol- Exposed Pregnancies. A Report of the National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect. Available at: www.cdc.gov/ncbddd/fasd/documents/redalcohpreg.pdf. Accessed on February 19, 2016.
25.Floyd, R, Jack, B, Cefalo, R, et al. The clinical content of preconception care: alcohol, tobacco, and illicit drug exposures. Am J Obstet Gynecol. 2008;199:S333–9.
26.Chen, L, Strain, E, Crum, R, Mojtabai, R. Gender differences in substance abuse treatment and barriers to care among persons with substance use disorders with and without comorbid major depression. J Addict Med. 2013;7:325–34.
27.Dutra, L, Stathopoulou, G, Basden, S, et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165:179–87.
28.Finfgeld-Connett, D, Johnson, E. Substance abuse treatment for women who are under correctional supervision in the community: a systematic review of qualitative findings. Issues Ment Health Nurs. 2011;32:640–8.
30.Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers and other drugs among women – United States, 1999–2010. MMWR (Morb Mortal Wkly Rep). 2013;62:537–42.
31.Unger, A, Jung, E, Winklbaur, B, Fischer, G. Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine. J Addict Dis. 2010;29:217–30.
32.Jones, H, Kaltenbach, K, Heil, S, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320–31.
33.Amato, L, Minozzi, S, Davoli, M, Vecchi, S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011 Oct 5;10:CD004147.
34.Metsch, L, McCoy, H, McCoy, C, et al. Use of health care services by women who use crack cocaine. Women & Health. 1999;30:35–51.
35.Schottenfeld, R, Moore, B, Pantalon, M. Contingency management with community reinforcement approach or twelve-step facilitation drug counseling for cocaine dependent pregnant women or women with young children. Drug Alcohol Depend. 2011;118:48–55.
37.Danovitch, I, Gorelick, D. State of the art treatments for cannabis dependence. Psychiatr Clin North Am. 2012;35:309–26.
38.Gray, K, Carpenter, M, Baker, N, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012;169:805–12.
39.Knight, J, Sherritt, L, Shrier, L, et al. Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Arch Pediatr Adolesc Med. 2002;156:607–14.
40.Mitchell, S, Kelly, S, Gryczynski, J, et al. The CRAFFT cut-points and DSM-5 criteria for alcohol and other drugs: a reevaluation and reexamination. Subst Abus. 2014;35(4):376–80.
41.Das, S, Rao, V, Chaudhuri, J. Preconception counseling in the prevention of fetal alcohol syndrome: a unique window of opportunity. Clin Ter. 2009;160:315–22.
42.Grant, T, Ernst, C, Streissguth, A. An intervention with high-risk mothers who abuse alcohol and drugs: the Seattle Advocacy Model. Am J Public Health. 1996;86:1816–17.
43.American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 121: long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol. 2011;118:184–96.
44.American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 112: emergency contraception. Obstet Gynecol. 2010;115:1100–9.
45.Meyers, D, Wolff, T, Gregory, K, Marion, L, Moyer, V, Nelson, H, et al. USPSTF recommendations for STI screening. Am Fam Physician. 2008;77:819–924.
46.American college of Obstetricians and Gynecologists: ACOG Committee Opinion no 596: Committee on Gynecologic Practice: Routine human immunodeficiency virus screening. Obstet Gynecol. 2014;123(5): 137–139.
47.Massad, L, Einstein, M, Huh, W, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013 Apr;121(4):829–46.
48.Calhoun, F, Attilia, M, Spagnolo, P, et al. National Institute on Alcohol Abuse and Alcoholism and the study of fetal alcohol spectrum disorders. The International Consortium. Ann Ist Super Sanita. 2006;42:4–7.
49.Frank, D, Augustyn, M, Knight, W, et al. Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review. JAMA. 2001;285:1613–25.
50.McLellan, A, Lewis, D, O’Brien, C, Kleber, H. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689–95.